G-CSF IMPROVES TREG SELECTION AND OUTCOMES OF HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH T CELL ADOPTIVE IMMUNOTHERAPY (EHA 2025) - May 16, 2025 - Abstract #S264; Pres time: Jun 13, 2025; 06:00 PM - 06:15 PM; Location: Brown Hall 3; "Immune reconstitution was good as viral reactivation occurred only in the early phase after transplant and did not cause any deaths (18 patients (58%) required treatment for HHV6 reactivation in the first month; 5 patients (16%) required treatment of CMV disease after Letermovir prophylaxis)... Treg selection from G-CSF stimulated donors allows for higher purity of Treg final product and its use, together with unstimulated donor Tcons, resulted in lower incidence of aGVHD, even in the absence of immunosuppression, maintaining a potent antileukemic effect. Our study supports the use of Stim-Tregs for immune-suppression free HLA-haploidentical HSCT with Treg-Tcon adoptive immunotherapy."
IO biomarker • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Myelodysplastic Syndrome • Oncology • Pneumonia • Respiratory Diseases • Stomatitis • T Acute Lymphoblastic Leukemia • Transplantation • CD34 • FOXP3 • IL2RA • IL7R • ISG20
|
|
Loredana Ruggeri; Rebecca Sembenico; Simonetta Saldi; Valerio Viglione; Francesco Zorutti; Anna Castaldo; tiziana zei; roberta iacucci ostini; Antonella Mancusi; Alessandra Cipiciani; Matteo Caridi; Karim Enrico Jardini; Eni Hoxha; Valeria Cardinali; Roberta La Starza; Cristina Mecucci; Andrea Velardi; Massimo Fabrizio Martelli; Maria Paola Martelli; Cynthia Aristei; Alessandra Carotti; Antonio Pierini
|